
A new class of drugs is entering myeloma clinical trials. These checkpoint inhibitors take the "brakes" off the immune system so it can do it's job to kill the myeloma cells. To learn more about how this class of drugs works, click here. This new drug, called nivolumab, is now being tested in a Phase II clinical trial in combination with dexamethasone and lenalidomide to determine if it can help prevent or postpone smoldering myeloma from progressing to active myeloma. The trial will enroll 41 patients and will be open in both Beth Israel Deaconess Medical Center and the Dana Farber Cancer Institute in Boston. Click here to learn more about the clinical trial: Nivolumab, Rev, Dex Smoldering Myeloma Clinical Trial

about the author
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd).
More on New in Myeloma
Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:






.svg_7bb6fd32-1b73-4ca9-9a2f-8fd6fc59d528.png?alt=media)